The goal of this clinical trial is to learn if nebulized ketamine helps treat moderate to severe asthma attacks in adults in the emergency department. It will also learn about the safety of ketamine when inhaled through a nebulizer. The main questions it aims to answer are: * Does nebulized ketamine improve breathing more than standard treatment alone? * What side effects, if any, do participants experience after receiving nebulized ketamine? Researchers will compare nebulized ketamine to a placebo (a saltwater mist with no medication) to see how well it works and how safe it is. Participants will: * Receive either nebulized ketamine or a placebo mist, along with standard asthma treatment * Have their breathing checked before and after treatment using a peak flow meter * Be monitored for 60 minutes and have their symptoms, vital signs, and any side effects recorded
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
100
\*\*Intervention Description:\*\* Nebulized ketamine is administered as a single dose of 0.5 mg/kg of ketamine hydrochloride diluted in 0.9% normal saline to a total volume of 5ml. The solution is delivered via a standard jet nebulizer over approximately 15-20minutes. This intervention is given once at the time of enrollment in the emergency department, in addition to standard asthma care. The ketamine used is in injectable solution form (typically 50 mg/mL concentration), drawn and diluted immediately prior to nebulization. Participants are monitored continuously for 60 minutes after administration to assess changes in peak expiratory flow rate (PEFR), symptom relief, and adverse events. The goal is to evaluate the bronchodilatory effect and safety of nebulized ketamine in adults with moderate to severe asthma exacerbation who present to the emergency department.
\*\*Intervention Description (Control Group):\*\* Participants in the control group will receive a single nebulized dose of 5 mL of 0.9% normal saline, delivered using a standard jet nebulizer over approximately 10-15 minutes. This placebo intervention is administered once at the time of enrollment in the emergency department, after standard asthma care. Standard care includes repeated doses of nebulized salbutamol and ipratropium, systemic corticosteroids (oral or intravenous), and supplemental oxygen as needed. The placebo solution is identical in appearance and volume to the active ketamine solution used in the intervention group to maintain blinding. All participants will be monitored for 60 minutes after nebulization to assess changes in peak expiratory flow rate (PEFR), symptom relief using a visual analog scale (VAS), and the occurrence of any adverse events.
Change in Peak Expiratory Flow Rate (PEFR) from baseline to 60 minutes post-intervention
PEFR will be measured using a peak flow meter at baseline (0 minutes) and at 60 minutes after administration of the intervention. The change in PEFR will be calculated to assess the intervention effect.
Time frame: Baseline (0 minutes) and 60 minutes post-intervention
Change in PEFR at 30 minutes
Time frame: 30 minutes
• Incidence of adverse effects
Time frame: 60 minutes
Incidence of intravenous magnesium sulfate administration
The proportion of participants who receive intravenous magnesium sulfate as part of escalation of care after 60 minutes post-intervention.
Time frame: 60 minutes
Incidence of ICU admission
The proportion of participants who require transfer to an intensive care unit (ICU) after 60 minutes post-intervention.
Time frame: 60 minutes
Incidence of endotracheal intubation
The proportion of participants who undergo endotracheal intubation after 60 minutes post-intervention due to clinical deterioration.
Time frame: 60 minutes
Incidence of non-invasive ventilation (BiPAP) initiation
The proportion of participants who require initiation of bilevel positive airway pressure (BiPAP) after 60 minutes post-intervention as part of escalation of care.
Time frame: 60 minutes
Disposition plan (discharged, admitted, or transferred)
Time frame: 60 minutes
Length of stay (if admitted)
Time frame: 60 minutes
Type of admission bed (e.g., ward vs. ICU)
Time frame: 60 minutes
Change in dyspnea severity as measured by the Visual Analogue Scale (VAS)
Patient-reported breathlessness will be assessed using the Visual Analogue Scale (VAS), a 10-centimeter horizontal line ranging from 0 to 10. A score of 0 represents "no breathlessness," and a score of 10 represents "worst imaginable breathlessness." The change in VAS score from baseline to 60 minutes post-intervention will be recorded.
Time frame: 60 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.